These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
129 related items for PubMed ID: 35180142
1. Vitamin B12 enhances the antitumor activity of 1,25-dihydroxyvitamin D3 via activation of caspases and targeting actin cytoskeleton. Atoum MF, Alzoughool FE, Al-Mazaydeh ZA, Rammaha MS, Tahtamouni LH. Tumour Biol; 2022; 44(1):17-35. PubMed ID: 35180142 [Abstract] [Full Text] [Related]
2. 1α,25-Dihydroxyvitamin D3 synergistically enhances anticancer effects of ginsenoside Rh2 in human prostate cancer cells. Ben-Eltriki M, Deb S, Guns EST. J Steroid Biochem Mol Biol; 2021 May; 209():105828. PubMed ID: 33493594 [Abstract] [Full Text] [Related]
3. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Ravid A, Rocker D, Machlenkin A, Rotem C, Hochman A, Kessler-Icekson G, Liberman UA, Koren R. Cancer Res; 1999 Feb 15; 59(4):862-7. PubMed ID: 10029076 [Abstract] [Full Text] [Related]
4. 1,25-Dihydroxyvitamin D3 suppresses gastric cancer cell growth through VDR- and mutant p53-mediated induction of p21. Li M, Li L, Zhang L, Hu W, Shen J, Xiao Z, Wu X, Chan FL, Cho CH. Life Sci; 2017 Jun 15; 179():88-97. PubMed ID: 28465245 [Abstract] [Full Text] [Related]
5. 1,25-Dihydroxyvitamin D₃ and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells. Bao A, Li Y, Tong Y, Zheng H, Wu W, Wei C. Int J Mol Med; 2014 May 15; 33(5):1177-84. PubMed ID: 24573222 [Abstract] [Full Text] [Related]
6. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. Cancer Biol Ther; 2007 Jan 15; 6(1):48-55. PubMed ID: 17172823 [Abstract] [Full Text] [Related]
7. Prevention of preneoplastic mammary lesion development by a novel vitamin D analogue, 1alpha-hydroxyvitamin D5. Mehta RG, Moriarty RM, Mehta RR, Penmasta R, Lazzaro G, Constantinou A, Guo L. J Natl Cancer Inst; 1997 Feb 05; 89(3):212-8. PubMed ID: 9017001 [Abstract] [Full Text] [Related]
8. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2]. Lu HQ, Zheng J. Ai Zheng; 2006 Dec 05; 25(12):1470-6. PubMed ID: 17166369 [Abstract] [Full Text] [Related]
9. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Ly LH, Zhao XY, Holloway L, Feldman D. Endocrinology; 1999 May 05; 140(5):2071-6. PubMed ID: 10218956 [Abstract] [Full Text] [Related]
10. 1,25-Dihydroxy vitamin D3 inhibits the Ras-MEK-ERK pathway and regulates proliferation and apoptosis of papillary thyroid carcinoma. Li B, Lv L, Li W. Steroids; 2020 Jul 05; 159():108585. PubMed ID: 31982425 [Abstract] [Full Text] [Related]
11. Fish oil enhances the antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 on liver cancer cells. Chiang KC, Persons KS, Istfan NW, Holick MF, Chen TC. Anticancer Res; 2009 Sep 05; 29(9):3591-6. PubMed ID: 19667153 [Abstract] [Full Text] [Related]
12. Novel analogs of 1,25-dihydroxyvitamin D2 combined with a plant polyphenol as highly efficient inducers of differentiation in human acute myeloid leukemia cells. Nachliely M, Sharony E, Kutner A, Danilenko M. J Steroid Biochem Mol Biol; 2016 Nov 05; 164():59-65. PubMed ID: 26365556 [Abstract] [Full Text] [Related]
13. Differentiating and antitumor activities of 1 alpha,25-dihydroxyvitamin D3 in vitro and 1 alpha-hydroxyvitamin D3 in vivo on human osteosarcoma. Tsuchiya H, Morishita H, Tomita K, Ueda Y, Tanaka M. J Orthop Res; 1993 Jan 05; 11(1):122-30. PubMed ID: 8423514 [Abstract] [Full Text] [Related]
14. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Gavrilov V, Steiner M, Shany S. Anticancer Res; 2005 Jan 05; 25(5):3425-9. PubMed ID: 16101159 [Abstract] [Full Text] [Related]
15. Vitamin K2 enhances the tumor suppressive effects of 1,25(OH)2D3 in triple negative breast cancer cells. Narvaez CJ, Bak MJ, Salman N, Welsh J. J Steroid Biochem Mol Biol; 2023 Jul 05; 231():106307. PubMed ID: 37030416 [Abstract] [Full Text] [Related]
16. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer. Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF. Clin Cancer Res; 2000 Mar 05; 6(3):901-8. PubMed ID: 10741714 [Abstract] [Full Text] [Related]
17. Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Simboli-Campbell M, Narvaez CJ, van Weelden K, Tenniswood M, Welsh J. Breast Cancer Res Treat; 1997 Jan 05; 42(1):31-41. PubMed ID: 9116316 [Abstract] [Full Text] [Related]
18. Induction of apoptosis and inhibition of prostate and breast cancer growth by BGP-15, a new calcipotriene-derived vitamin D3 analog. Berkovich L, Ben-Shabat S, Sintov AC. Anticancer Drugs; 2010 Jul 05; 21(6):609-18. PubMed ID: 20335794 [Abstract] [Full Text] [Related]
19. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Moffatt KA, Johannes WU, Miller GJ. Clin Cancer Res; 1999 Mar 05; 5(3):695-703. PubMed ID: 10100724 [Abstract] [Full Text] [Related]
20. Characterization of a vitamin D3-resistant MCF-7 cell line. Narvaez CJ, Vanweelden K, Byrne I, Welsh J. Endocrinology; 1996 Feb 05; 137(2):400-9. PubMed ID: 8593782 [Abstract] [Full Text] [Related] Page: [Next] [New Search]